The Journal of Heart and Lung Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

End-of-Life Care for Lung Transplant Recipients: A New Role for Palliative Medicine
Purpose: Little is known about the palliative care needs of lung transplant recipients (LTR), especially in their end-of-life phase. We reviewed the characteristics of LTR referred for co-management by palliative care (PC) at our centre. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M. Pappalettera, V. Rossetti, I. Righi, F. Damarco, M. Nosotti, R. Moroni Grandini, F. Blasi Source Type: research

Efficacy of Short Course Direct Acting Antivirals and Ezetimibe vs Longer Course of Direct Acting Antivirals to Prevent Hepatitis C Infection in Thoracic Transplant Recipients of Hepatitis C Viremic Donors
Purpose: Heart and lung transplantation are lifesaving procedures but are limited by the ongoing shortage of donors. Pan-genotypic direct acting antivirals (DAA) and HCV entry blockers have allowed centers to utilize HCV positive organs for HCV negative recipients, increasing the pool of available donors. However, the optimal duration of this therapy has not been established. We evaluated if a DAA combined with an HCV entry blocker given for 14 days was associated with similar outcomes compared to a regimen of DAA alone given for 28 days in preventing HCV infection in heart and lung recipients receiving organs from HCV nuc...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , T. Fallah, B.A. Whitson, B.C. Lampert, J.P. Rosenheck, A.M. Ganapathi, M.C. Henn, N. Marschalk, K.T. Kissling Source Type: research

Prophylaxis of Donor-Derived HCV Infection in Cardiothoracic Transplant Recipients with Short-Course DAA Therapy
Purpose: Acceptance of hepatitis C virus (HCV) viremic organs has increased access to cardiothoracic transplant. However, standard 8-12 week HCV treatment courses increase cost and treatment burden to transplant recipients with unknown long-term effects on the allograft. We aimed to prevent transmission of HCV from HCV-viremic donors to uninfected cardiothoracic transplant recipients with a peri-operative short course of direct acting antiviral (DAA). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Aslam Source Type: research

Intermediate Term Outcomes of CAV Screening in Heart Transplant Recipients from Hepatitis C Viremic Donors versus Non-Hepatitis C Donors
We report 5-year outcomes from routine annual CAV screening by intravascular ultrasound (IVUS) in HCV-viremic donors [nucleic amplification test: NAT (+)] vs non-viremic donors: NAT (-). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Birs, E. Adler, K. Hong, S. Aslam, N. Wettersten Source Type: research

Impact and Outcomes of Hepatitis C Viremic Donors (HCV-NAAT) on Donor-Derived Cell-Free DNA Levels and Gene-Expresion Profiling (GEP-Allomap) in Heart Transplant Recipients
Purpose: Scarcity of donor availability has led to increased rates of HCV viremic donors (NAAT+). We aimed to assess the impact of NAAT+ donors on dd-cfDNA and GEP results in Heart Transplantrecipients. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , A. Fernandez Valledor, D. Oren, A. Rahman, G. Rubinstein, S. Rahman, C. Lee, J. Baranowska, M. Regan, Y. Mehlman, D. Lotan, E.M. DeFilippis, K. Theodoropoulos, J. Fried, V. Topkara, D. Majure, P. Colombo, J. Raikhelkar, M. Yuzefpolskaya, K. Clerkin, F. Source Type: research

Racial and Ethnic Disparities in Transplantation of Hearts from HCV-Infected Donors into HCV-Negative Recipients
Purpose: Transplanting organs from hepatitis c virus (HCV) infected donors into HCV-negative recipients has led to thousands of more transplants in the US since 2016. Studies have demonstrated disparities in utilization of kidneys from these donors along the lines of gender and education. It is still unknown, however, if the same disparities are seen in heart transplantation. The goal of this study was to determine if there were disparities present in the receipt of HCV infected donor hearts. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , D. Goldberg Source Type: research

Impact of Concomitant Aortic Valve Replacement in Patients with Mild-to-Moderate Aortic Valve Regurgitation Undergoing LVAD Implantation: Propensity Score-Matched Analysis of the EUROMACS Dataset
In this study we compared the outcomes of LVAD patients with preoperative mild-to-moderate AR who underwent a concomitant aortic valve replacement (AVR) to those in whom AR was left untreated. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , G. Nersesian, G. Gliozzi, G. Gallone, A. Spitaleri, F. Schoenrath, I. Netuka, D. Zimpfer, T. De By, M. Boffini, I. Vendramin, J. Gummert, V. Falk, B. Meyns, M. Rinaldi, E. Potapov Source Type: research

Cryoablation for Ventricular Arrhythmia During Left Ventricular Assist Device Implantation is Safe and Feasible: A Retrospective Cohort Study
This study aims to evaluate the safety and efficacy of a novel treatment, concomitant surgical cryoablation with LVAD implantation, in reducing post-operative VAs. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , I. Bhatia, O.J. Lee, C. Ho Source Type: research

Incidence and Risk Factors for Early Stroke Following Durable Left Ventricular Assist Device (LVAD) Implantation: An STS Intermacs Analysis
Purpose: Stroke remains a devastating complication of durable LVAD therapy. Pre-implant patient factors have traditionally been used to predict the risk of post-implant stroke. The purpose of this study was to evaluate the incidence and risk factors for early stroke within 7 days following LVAD implantation with particular attention to the impact of intraoperative variables. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , D. Goldstein, R. Cantor, M. Kanwar, D. Meyer, U. Jorde, O. Saeed, K. Wood, R. Rudraraju, S. Lewis, J. Kirklin, F. Pagani, A. Kilic Source Type: research

Mitral Regurgitation at the Time of Left Ventricular Assist Device Implantation - Should We Treat It or Not?
Purpose: Mitral regurgitation (MR) is a common manifestation of advanced heart failure and may persist or progress after LVAD implantation. Because of the unclear benefit of correcting MR in patients with an LVAD, it remains to be determined whether MR should be surgically treated at the time of implantation. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , G. Matsumiya, Y. Saiki, K. Kinugawa, M. Ono Source Type: research

Impact of Concomitant Surgical Procedures in a Randomized Controlled Trial of Aspirin Removal in Left Ventricular Assist Device Patients - An Analysis from The ARIES Trial
Purpose: ARIES is an international, placebo-controlled, study of aspirin (100mg daily) in patients implanted with the HM3 LVAD to demonstrate that elimination of aspirin from the antithrombotic regimen preserves safety and efficacy and reduces residual risk of non-surgical bleeding complications. The primary endpoint results of the ARIES HM3 Trial will be presented in November 2023. In this analysis, we seek to analyze the impact of concomitant procedures (stratified by valvular and non-valvular surgery) on hemocompatibility related outcomes within the study. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , M.R. Mehra Source Type: research

Improved Equity in 1A, but Not 1B, Status Exceptions for Pediatric Heart Transplant Candidates with Pediatric Specific Review Board and Exception Guidance
Purpose: The creation of a national heart review board (NHRB) specific to pediatric candidates and release of an exception guidance document to standardize decision-making were recently implemented in the US to reduce variability and ensure equity in status exceptions for pediatric heart transplant candidates. We evaluated the hypothesis that these changes decreased center variability and racial disparities within the granted exceptions. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , S. Culp, R.J. Gajarski, D. Nandi Source Type: research

The TEAMMATE Trial: Post-Transplant Outcomes and Social Determinants of Health
We report on the association of social determinants of health (SDOH) to outcomes; and treatment effects (currently embargoed) according to SDOH. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , T.P. Singh, K.P. Daly, J.C. Alejos, S.R. Auerbach, L. Barkoff, M.J. Bock, A. Butto, W.F. Carlo, C. Castleberry, M. Chrisant, S. Deshpande, W.J. Dreyer, B. Feingold, J. Friedland-Little, S. Gonzales, S.A. Hollander, A. Joong, S. Kindel, G.L. Klein, A.K. Source Type: research

Socioeconomic Deprivation Predicts Worse Post-Transplant Survival in US Pediatric Heart Transplantation
Purpose: To evaluate the impact of social determinants of health (SDOH) on pediatric heart transplantation (HTx). (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , J. Greenberg, J. Kennedy, C. Chin, T. Ryan, S. de Loizaga Carney, K. Schneider, A.A. Divanovic, F. Zafar, D.L. Morales Source Type: research

Availability, Volumes, and Referral Strategies of Advanced Heart Failure Therapies in the Eastern Mediterranean Region: Results from The AHF-EMR Survey
Purpose: The Eastern Mediterranean Region (EMR) consists of 21 countries and one territory with a population of almost 745 million. Despite the global downtrend in advanced heart failure (AHF) prevalence in the last three decades, the EMR is experiencing a growing burden. Data on AHF therapies (AHFT) in the EMR are scarce and primarily limited to single-center experiences. The AHF-EMR survey aims to quantify the availability and volumes of AHFT [including left ventricular assist devices (LVAD) and heart transplantation (HTx)], describe referral strategies for AHFT abroad, and underscore current challenges in AHF care in th...
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: Y. Manla, , F. Khaliel, M. Yacoub, K. Shaker, A. Amin, R. Tarazi, K. Alhumood, H. Skouri, A. Badr, A. Bennis, L. Abid, A. Turk, A. Abdin, N. Elsammani, N. Paktin, S. Bhatti, O. Bheleel, H. Farhan, K. Sulaiman, A. Al-Motarreb, M. AlQaseer, F. Bader Source Type: research